Adicet Bio Expands into Autoimmune Diseases with Allogeneic Gamma Delta T Cell Therapy

Adicet Bio's Expansion:
Adicet Bio has received Fast Track Designation from the FDA for its allogeneic gamma delta T cell therapy, ADI-001, for treating relapsed/refractory class III or class IV lupus nephritis, marking a significant step into autoimmune disease treatment.

Clinical Trials:
The company plans to initiate a Phase 1 clinical study in lupus nephritis and is also evaluating ADI-001 in a Phase 1 study for B-cell non-Hodgkin lymphoma.

Therapeutic Potential:
ADI-001 has shown robust B-cell depletion and favorable safety data, making it a promising candidate for autoimmune diseases, particularly those requiring targeted B-cell depletion.

Industry Trend:
The redirection of cell therapy to autoimmune diseases is part of a broader industry trend, with at least 33 ongoing clinical trials evaluating cell therapies for various autoimmune indications.

Competitive Landscape:
Other companies, such as Cabaletta Bio, are also exploring CAR T-cell therapies for autoimmune diseases, including systemic lupus erythematosus (SLE) and lupus nephritis.

Future Plans:
Adicet Bio aims to provide a comprehensive update on its autoimmune program and plans to transition ADI-001 into a potential pivotal Phase 2 study in post-CAR T LBCL in the first half of 2024.